1. TTN-AS1 accelerates the growth and migration of nasopharyngeal carcinoma cells via targeting miR-876-5p/NETO2
- Author
-
Xiaojuan Li, Xinping Chen, Junjie Hu, Weihua Xu, Juan Zhu, Shengmiao Fu, and Zhichao Ma
- Subjects
Cancer Research ,TTN-AS1 ,Cell ,miR-876-5p ,Biology ,NETO2 ,High morbidity ,otorhinolaryngologic diseases ,medicine ,Pharmacology (medical) ,Tumor growth ,Multiple tumors ,RC254-282 ,YY1 ,Cell growth ,nasopharyngeal carcinoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,stomatognathic diseases ,medicine.anatomical_structure ,Oncology ,Nasopharyngeal carcinoma ,Apoptosis ,UPF1 ,Cancer research ,Molecular Medicine - Abstract
Nasopharyngeal carcinoma (NPC) is one of the most predominant cancers occurring in China with high morbidity. Lately, large quantities of long non-coding RNAs (lncRNAs) have been highlighted to regulate the biological activities in multiple tumors, including NPC. Our study centered on whether TTN-AS1 was involved in NPC and how it modulated the progression of NPC. Here, RT-qPCR data uncovered that TTN-AS1 expression was conspicuously high in NPC cells. Based on the results of functional assays, TTN-AS1 silence hampered the proliferative, migratory and invasive abilities but stimulated apoptotic capability of NPC cells. After a series of mechanism assays, TTN-AS1 was found to competitively bind with miR-876-5p and recruit UPF1 to enhance NETO2 expression. In addition, TTN-AS1 could be transcriptionally activated by YY1 in NPC cells. It was also found miR-876-5p overexpression or NETO2 down-regulation had inhibitory effects on cell proliferation, migration and invasion in NPC. Moreover, NETO2 up-regulation could restore the suppressive impacts of TTN-AS1 depletion on NPC cell and tumor growth. In conclusion, YY1-activated TTN-AS1 interacted with both miR-876-5p and UPF1 to up-regulate NETO2, thus strengthening NPC cell malignant behaviors, which might provide more useful information for people to develop effective NPC treatments.
- Published
- 2022